Queensland's Ban Is a Bureaucratic Knife Dressed as a Deadline

The Queensland government looked at its own review, the one that said the ban on puberty blockers creates legal, ethical, governance, regulatory, and oversight risks, the one that found low-quality but consistent evidence that the medication reduces gender-related distress when carefully prescribed, and the health minister's response was to point at 2031 like it was a destination instead of a stall tactic. A trial in another country that hasn't even reported yet. That's the evidence base for leaving trans kids in Queensland without care for the better part of a decade. Not science. A calendar entry.

The federal government stepping in to fund leuprorelin through the PBS is real, and it matters, and it will help kids who would otherwise have nothing. That's not nothing. But calling it a solution is the kind of generous framing that lets the people who created the problem off the hook, because what the PBS listing actually is, is a workaround for a ban that never should have existed, a way to partially reopen a door that a state government slammed shut for reasons that don't survive contact with their own commissioned evidence. The drug has been available since 2006. For prostate cancer. The molecule didn't change. The patients did, and apparently that's the variable that matters to Queensland's health ministry.

There's something specifically enraging about the "we need more evidence" framing when the evidence already in hand was good enough to flag the ban's own risks, when the drug in question has decades of clinical use, when the people most affected are adolescents whose bodies are not waiting for a 2031 report to finish developing. Puberty doesn't file for an extension. The distress that blockers are designed to interrupt doesn't pause while a trial cohort in another hemisphere completes its follow-up. The ban doesn't stop time. It just stops treatment, and the kids absorb the difference in ways that don't show up cleanly in whatever review the minister is waiting for.

What the federal workaround can't fix is the underlying logic that produced the ban, the idea that trans kids' access to care is a legitimate site of political contestation in a way that other pediatric endocrinology simply isn't. Nobody is holding press conferences about the evidence base for treating precocious puberty. Nobody is commissioning five-year reviews before prescribing growth hormone to kids whose bodies aren't developing on the expected timeline. The scrutiny is not about the science. It's about who the patients are, and a PBS listing, as genuinely useful as it is, doesn't touch that. The system that decided these particular kids needed a higher evidentiary bar than every other patient population is still running, still making decisions, still capable of finding the next reason to delay.

So yes, the federal move is worth something. Kids who needed access and didn't have it may now get it, and that is not a small thing when you're talking about adolescents in distress. But the state government is still in place, the ban is still the policy, and the minister is still pointing at 2031 with the confidence of someone who has decided that other people's urgency is not their problem. That's not a solved situation. That's a partially-blocked drain with a bucket underneath it, and someone is going to have to keep emptying the bucket until somebody fixes the pipe.